Head-To-Head Analysis: Aurinia Pharmaceuticals (NASDAQ:AUPH) & PMV Pharmaceuticals (NASDAQ:PMVP)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and PMV Pharmaceuticals (NASDAQ:PMVP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Aurinia Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aurinia Pharmaceuticals and PMV Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	0	2.40
PMV Pharmaceuticals	1	0	1	0	2.00

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, indicating a potential upside of 16.23%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 267.65%. Given PMV Pharmaceuticals’ higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Earnings and Valuation

This table compares Aurinia Pharmaceuticals and PMV Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$265.81 million	7.54	$5.75 million	$0.56	27.14
PMV Pharmaceuticals	N/A	N/A	-$58.71 million	($1.60)	-0.85

Aurinia Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurinia Pharmaceuticals and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	23.31%	20.06%	13.81%
PMV Pharmaceuticals	N/A	-55.34%	-51.01%

Summary

Aurinia Pharmaceuticals beats PMV Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.